First Time Loading...

BRAIN Biotech AG
XETRA:BNN

Watchlist Manager
BRAIN Biotech AG Logo
BRAIN Biotech AG
XETRA:BNN
Watchlist
Price: 2.83 EUR 2.91%
Updated: Apr 26, 2024

Intrinsic Value

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. [ Read More ]

The intrinsic value of one BNN stock under the Base Case scenario is 6.97 EUR. Compared to the current market price of 2.83 EUR, BRAIN Biotech AG is Undervalued by 59%.

Key Points:
BNN Intrinsic Value
Base Case
6.97 EUR
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BRAIN Biotech AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BNN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
BRAIN Biotech AG

Provide an overview of the primary business activities
of BRAIN Biotech AG.

What unique competitive advantages
does BRAIN Biotech AG hold over its rivals?

What risks and challenges
does BRAIN Biotech AG face in the near future?

Summarize the latest earnings call
of BRAIN Biotech AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BRAIN Biotech AG.

Provide P/S
for BRAIN Biotech AG.

Provide P/E
for BRAIN Biotech AG.

Provide P/OCF
for BRAIN Biotech AG.

Provide P/FCFE
for BRAIN Biotech AG.

Provide P/B
for BRAIN Biotech AG.

Provide EV/S
for BRAIN Biotech AG.

Provide EV/GP
for BRAIN Biotech AG.

Provide EV/EBITDA
for BRAIN Biotech AG.

Provide EV/EBIT
for BRAIN Biotech AG.

Provide EV/OCF
for BRAIN Biotech AG.

Provide EV/FCFF
for BRAIN Biotech AG.

Provide EV/IC
for BRAIN Biotech AG.

Show me price targets
for BRAIN Biotech AG made by professional analysts.

What are the Revenue projections
for BRAIN Biotech AG?

How accurate were the past Revenue estimates
for BRAIN Biotech AG?

What are the Net Income projections
for BRAIN Biotech AG?

How accurate were the past Net Income estimates
for BRAIN Biotech AG?

What are the EPS projections
for BRAIN Biotech AG?

How accurate were the past EPS estimates
for BRAIN Biotech AG?

What are the EBIT projections
for BRAIN Biotech AG?

How accurate were the past EBIT estimates
for BRAIN Biotech AG?

Compare the revenue forecasts
for BRAIN Biotech AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BRAIN Biotech AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BRAIN Biotech AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of BRAIN Biotech AG compared to its peers.

Compare the P/E ratios
of BRAIN Biotech AG against its peers.

Discuss the investment returns and shareholder value creation
comparing BRAIN Biotech AG with its peers.

Analyze the financial leverage
of BRAIN Biotech AG compared to its main competitors.

Show all profitability ratios
for BRAIN Biotech AG.

Provide ROE
for BRAIN Biotech AG.

Provide ROA
for BRAIN Biotech AG.

Provide ROIC
for BRAIN Biotech AG.

Provide ROCE
for BRAIN Biotech AG.

Provide Gross Margin
for BRAIN Biotech AG.

Provide Operating Margin
for BRAIN Biotech AG.

Provide Net Margin
for BRAIN Biotech AG.

Provide FCF Margin
for BRAIN Biotech AG.

Show all solvency ratios
for BRAIN Biotech AG.

Provide D/E Ratio
for BRAIN Biotech AG.

Provide D/A Ratio
for BRAIN Biotech AG.

Provide Interest Coverage Ratio
for BRAIN Biotech AG.

Provide Altman Z-Score Ratio
for BRAIN Biotech AG.

Provide Quick Ratio
for BRAIN Biotech AG.

Provide Current Ratio
for BRAIN Biotech AG.

Provide Cash Ratio
for BRAIN Biotech AG.

What is the historical Revenue growth
over the last 5 years for BRAIN Biotech AG?

What is the historical Net Income growth
over the last 5 years for BRAIN Biotech AG?

What is the current Free Cash Flow
of BRAIN Biotech AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for BRAIN Biotech AG.

Financials

Balance Sheet Decomposition
BRAIN Biotech AG

Current Assets 22.1m
Other Current Assets 22.1m
Non-Current Assets 44.4m
Other Non-Current Assets 44.4m
Current Liabilities 13.4m
Other Current Liabilities 13.4m
Non-Current Liabilities 32.6m
Other Non-Current Liabilities 32.6m
Efficiency

Earnings Waterfall
BRAIN Biotech AG

Revenue
55.2m EUR
Cost of Revenue
-24.2m EUR
Gross Profit
31m EUR
Operating Expenses
-36.7m EUR
Operating Income
-5.7m EUR
Other Expenses
-2.7m EUR
Net Income
-8.4m EUR

Free Cash Flow Analysis
BRAIN Biotech AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BNN Profitability Score
Profitability Due Diligence

BRAIN Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
29/100
Profitability
Score

BRAIN Biotech AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

BNN Solvency Score
Solvency Due Diligence

BRAIN Biotech AG's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

BRAIN Biotech AG's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNN Price Targets Summary
BRAIN Biotech AG

Wall Street analysts forecast BNN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNN is 10.27 EUR with a low forecast of 4.14 EUR and a high forecast of 15.75 EUR.

Lowest
Price Target
4.14 EUR
46% Upside
Average
Price Target
10.27 EUR
263% Upside
Highest
Price Target
15.75 EUR
457% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BNN Price
BRAIN Biotech AG

1M 1M
-18%
6M 6M
-24%
1Y 1Y
-54%
3Y 3Y
-67%
5Y 5Y
-73%
10Y 10Y
-69%
Annual Price Range
2.83
52w Low
2.75
52w High
6.12
Price Metrics
Average Annual Return -11.56%
Standard Deviation of Annual Returns 20.92%
Max Drawdown -79%
Shares Statistics
Market Capitalization 61.8m EUR
Shares Outstanding 21 847 495
Percentage of Shares Shorted
N/A

BNN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

BRAIN Biotech AG Logo
BRAIN Biotech AG

Country

Germany

Industry

Chemicals

Market Cap

61.8m EUR

Dividend Yield

0%

Description

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

Contact

HESSEN
Zwingenberg
Darmstaedter Strasse 34-36
+49625193310.0
https://www.brain-biotech.de/

IPO

2016-02-09

Employees

293

Officers

Chairman of the Management Board & CEO
Mr. Adriaan Moelker
Co-Founder
Mr. Ulrich Putsch
CFO & Member of Management Board
Mr. Michael Schneiders
Vice President of Human Resources & Processes
Dr. Ute Dechert
Consultant
Dr. Jurgen Eck
MD & Executive VP
Dr. Martin Langer
Show More
VP and Head of Research & Development - Zwingenberg
Dr. Alexander Pelzer
Head of Group Finance
Mr. Robbert Michael Hoekstra
Technical Lead of Genome Editing Development
Mr. Paul Scholz
Show Less

See Also

Discover More
What is the Intrinsic Value of one BNN stock?

The intrinsic value of one BNN stock under the Base Case scenario is 6.97 EUR.

Is BNN stock undervalued or overvalued?

Compared to the current market price of 2.83 EUR, BRAIN Biotech AG is Undervalued by 59%.